指南与共识颈动脉与弓上血管

症状性颈动脉内膜切除术后患者对COMPASS试验药物推荐的接受度与依从性

Patient Acceptance and Adherence to the COMPASS Trial Drug Recommendations Following Symptomatic Carotid Endarterectomy.
指南 / 共识 · Ann Vasc Surg · 2024-07-14

本研究评估63例症状性颈动脉狭窄患者颈动脉内膜切除术后对COMPASS方案(低剂量利伐沙班联合阿司匹林)的接受度与依从性,并与54例单联抗血小板治疗患者比较。结果显示COMPASS组患者对服药必要性持强烈正面看法(必要性评分19.6±3.6),担忧程度不高(担忧评分11.8±4.9),必要性-担忧差值为正(7.8±6.2),药物依从性评分处于「高」至「好」水平(依从性水平1.7±1.0)。两组信念量表评分、依从性评分、主要不良心血管事件及副作用发生率均相似。

要点

  • 颈动脉内膜切除术后患者对COMPASS方案持积极态度,药物依从性高。
  • COMPASS组必要性评分19.6±3.6,担忧评分11.8±4.9,必要性-担忧差值为正7.8±6.2。
  • COMPASS组与单联抗血小板治疗组在信念评分、依从性、主要不良心血管事件及副作用方面相似。

核心结论

  • 颈动脉内膜切除术后使用COMPASS方案的患者对服药持积极看法且药物依从性高。
  • 未发现患者相关障碍影响COMPASS方案用于进一步减少心血管事件。

研究设计与样本

  • 研究纳入颈动脉内膜切除术后患者63例评估COMPASS方案,并与54例单联抗血小板治疗患者比较。
  • 采用信念 about 药物问卷评估患者观点,采用Sidorkiewicz评分系统判定药物依从性。
  • 记录副作用(出血和药物反应)及新发主要不良心血管事件。

主要发现

  • COMPASS组必要性评分19.6±3.6,担忧评分11.8±4.9,必要性-担忧差值7.8±6.2。
  • COMPASS组药物依从性评分处于「高」至「好」水平,依从性水平1.7±1.0。
  • COMPASS组与单联抗血小板治疗组的信念 about 药物问卷评分和药物依从性评分相似。
  • COMPASS组与单联抗血小板治疗组的主要不良心血管事件及副作用发生率相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The COMPASS trial demonstrated that in patients with atherosclerotic diseases, low-dose rivaroxaban and aspirin provides greater protection against subsequent major adverse cardiovascular events (MACEs) than mono-antiplatelet therapy (MAPT) alone. Drug acceptance and adherence maximizes this benefit. We have assessed drug acceptance and adherence to the COMPASS drug regime in patients following carotid endarterectomy (CEA) for symptomatic carotid artery stenosis. METHODS: Following CEA, the views of 63 patients on the COMPASS drug regime were assessed using the Beliefs about Medicine Questionnaire and drug adherence was determined using the Sidorkiewicz scoring system. These views were compared with those of 54 patients on MAPT. Side effects (bleeding and drug reactions) and new MACE were recorded. RESULTS: Post-CEA patients on the COMPASS drug regimen had strong positive views on the necessity to take these drugs (necessity scale 19.6 ± 3.6). Although there were some concerns about the COMPASS drug regimen, these were not strongly held (concern cscale 11.8 ± 4.9) and the necessity-concerns differential was positive (7.8 ± 6.2). The Drug Adherence Score was "High" to "Good" (level of drug adherence 1.7 ± 1.0). The Beliefs about Medicine Questionnaire scales and Drug Adherence Score of post-CEA patients on the COMPASS drug regimen were similar to those on MAPT. The incidence of post-CEA MACE and side effects were similar for those on the COMPASS drug regimen and MAPT. CONCLUSIONS: Post-CEA patients on the COMPASS drug regimen had positive views on taking the drugs and drug adherence was high. We did not identify any patient-related barriers to the use of the COMPASS drug regimen to further reduce cardiovascular events.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Baker D, Cruddas L, Eveson T, et al. Patient Acceptance and Adherence to the COMPASS Trial Drug Recommendations Following Symptomatic Carotid Endarterectomy. Ann Vasc Surg. 2024. PMID: 39009129. doi:10.1016/j.avsg.2024.05.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。